Johnson Huang is a prominent private equity investor and seasoned fund manager, currently serving as Director of the Private Equity IV Department at CICC Capital. As a member of the investment committee, He presides over the fundraising and ongoing management of private equity funds across both onshore RMB and offshore USD markets, with aggregate commitments exceeding USD 3 billion, primarily directed toward healthcare and artificial intelligence. His proven acumen spans the full cycle of fund formation, investment execution, and portfolio management in both currency regimes. Huang has personally orchestrated investments totalling over USD 1.5 billion, with a distinguished portfolio that includes JD Health (6618.HK), MicroPort CardioFlow (2160.HK), Endovastec (688016.SSE), Chemclin Diagnostics (688468.SSE), Giant Biogene (2367.HK), MicroPort Neurotech (2172.HK), Distinct Health (2677.HK), BrainAu (6681.HK), Metis TechBio (7666.HK), GRIT Therapeutics, and Adgenvax, among others. He also serves on the boards of multiple public companies, where he spearheads strategic expansion and value-creation initiatives.

Huang’s contributions have earned him a series of prestigious industry accolades, including Top 50 Healthcare Industry Leaders of China, Most Innovative Healthcare Venture Capitalist, 35 Under 35 Investor, and Forbes 30 Under 30.

Beyond commercial investing, he also chairs the RMB 1.6 billion Capital Healthtech Incubation Engineering Foundation – a non-profit dedicated to advancing healthcare innovation and public welfare. Huang holds a Bachelor of Science in Business and Finance from New York University.